DE68926431D1 - Nichtrevertierende lebende shigella-impfstoffe - Google Patents

Nichtrevertierende lebende shigella-impfstoffe

Info

Publication number
DE68926431D1
DE68926431D1 DE68926431T DE68926431T DE68926431D1 DE 68926431 D1 DE68926431 D1 DE 68926431D1 DE 68926431 T DE68926431 T DE 68926431T DE 68926431 T DE68926431 T DE 68926431T DE 68926431 D1 DE68926431 D1 DE 68926431D1
Authority
DE
Germany
Prior art keywords
change
gene
vaccines
host
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68926431T
Other languages
English (en)
Other versions
DE68926431T2 (de
Inventor
Bruce Stocker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of DE68926431D1 publication Critical patent/DE68926431D1/de
Application granted granted Critical
Publication of DE68926431T2 publication Critical patent/DE68926431T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE68926431T 1988-03-21 1989-03-02 Nichtrevertierende lebende shigella-impfstoffe Expired - Fee Related DE68926431T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/170,727 US5077044A (en) 1980-05-19 1988-03-21 Novel non-reverting shigella live vaccines
PCT/US1989/000847 WO1989009063A1 (en) 1988-03-21 1989-03-02 Novel non-reverting shigella live vaccines

Publications (2)

Publication Number Publication Date
DE68926431D1 true DE68926431D1 (de) 1996-06-13
DE68926431T2 DE68926431T2 (de) 1996-10-31

Family

ID=22621014

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68926431T Expired - Fee Related DE68926431T2 (de) 1988-03-21 1989-03-02 Nichtrevertierende lebende shigella-impfstoffe

Country Status (11)

Country Link
US (1) US5077044A (de)
EP (1) EP0368966B1 (de)
JP (1) JPH02503868A (de)
AT (1) ATE137673T1 (de)
AU (1) AU640344B2 (de)
CA (1) CA1335661C (de)
DE (1) DE68926431T2 (de)
FI (1) FI100945B (de)
HU (1) HU205262B (de)
PT (1) PT90075B (de)
WO (1) WO1989009063A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) * 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
IE61635B1 (en) * 1990-03-13 1994-11-16 Trinity College Dublin Improvements in vaccines
US5695983A (en) * 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
US5843426A (en) * 1990-12-18 1998-12-01 The General Hospital Corporation Salmonella vaccines
ATE173166T1 (de) * 1992-09-04 1998-11-15 Univ Saskatchewan Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
US5512288A (en) * 1992-12-04 1996-04-30 University Technologies International, Inc. Giardia vaccine
US5549899A (en) * 1992-12-04 1996-08-27 University Technologies International, Inc. Giardia vaccine
US5587305A (en) * 1993-12-06 1996-12-24 The United States Of America As Represented By The Department Of Agriculture Pasteurella haemolytica transformants
US6793927B1 (en) * 1993-12-06 2004-09-21 The United States Of America As Represented By The Secretary Of The Department Of Agriculture Construction of Pasteurella haemolytica vaccines
US6254874B1 (en) 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
EP0881884A4 (de) * 1995-09-06 2004-07-14 Dept Of The Army Us Government System zur verabreichung von bakterien
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US7045336B1 (en) 1995-09-06 2006-05-16 The United States Of America As Represented By The Secretary Of The Army Bacterial delivery system
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5783196A (en) * 1996-04-09 1998-07-21 University Of Maryland At Baltimore Gua mutants of shigella spp. and vaccines containing the same
WO1998051338A1 (en) * 1997-05-16 1998-11-19 U.S. Government, Department Of The Army U.S. Army Medical Research & Materiel Command Improved method for administration of vaccine against shigella infections
ATE512231T1 (de) 1998-02-27 2011-06-15 Univ Pennsylvania Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
KR20010103788A (ko) * 1999-03-03 2001-11-23 멕코나시 에블린 에이치. 백신 및 유전자요법 조성물 및 이들의 제조 및 사용방법
AU780887B2 (en) * 1999-04-09 2005-04-21 Zoetis Services Llc Anti-bacterial vaccine compositions
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
WO2000066162A1 (en) * 1999-04-30 2000-11-09 The Trustees Of The University Of Pennsylvania Mutant human cd80 and compositions for and methods of making and using the same
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
WO2002006303A2 (en) * 2000-07-14 2002-01-24 The Trustees Of The University Of Pennsylvania Dna vaccines encoding hiv accessory proteins
AU2002211524B2 (en) * 2000-10-04 2007-03-22 The Trustees Of The University Of Pennsylvania Highly expressible genes
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
EP1633372B1 (de) 2003-06-13 2011-11-30 The Trustees of The University of Pennsylvania Vakzine, immuntherapeutika und verfahren zu ihrer verwendung
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US20080274140A1 (en) * 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
CA2636867C (en) * 2006-01-13 2015-12-01 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
CA3184778A1 (en) 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
WO2010008411A1 (en) 2007-11-09 2010-01-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
CN105535961A (zh) * 2008-04-04 2016-05-04 宾夕法尼亚大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法
JP5744719B2 (ja) * 2008-04-04 2015-07-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法
AU2008363596B2 (en) 2008-10-29 2015-04-30 Inovio Pharmaceuticals, Inc Improved HCV vaccines and methods for using the same
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
JP2012508174A (ja) 2008-11-05 2012-04-05 ワイス・エルエルシー β溶血性連鎖球菌（ＢＨＳ）疾患を予防するための多成分免疫原性組成物
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
CN102821790A (zh) 2009-09-14 2012-12-12 宾夕法尼亚大学托管会 包含IL-15受体α和/或编码IL-15受体α的核酸分子的疫苗和免疫治疗剂,以及其使用方法
KR101851699B1 (ko) 2009-11-02 2018-04-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN102781952B (zh) 2010-02-08 2015-09-02 宾夕法尼亚大学托管会 编码rantes的核酸分子、包含其的组合物以及其使用方法
ES2718846T3 (es) 2010-11-12 2019-07-04 Univ Pennsylvania Antígenos de próstata consenso, molécula de ácido nucleico que los codifica y la vacuna y usos que los comprenden
CA2826199A1 (en) 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EA037377B1 (ru) 2011-02-11 2021-03-22 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Вакцина для индукции иммунного ответа на hbv
JP6117781B2 (ja) 2011-07-11 2017-04-19 イノビオ ファーマシューティカルズ，インコーポレイティド 交差防御性アレナウイルスワクチンおよびそれらの使用方法
CA2848658C (en) 2011-10-12 2022-08-02 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
WO2013062507A1 (en) 2011-10-24 2013-05-02 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
KR20140116095A (ko) 2011-12-12 2014-10-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Mrsa pbp2a 및 이의 단편들을 포함하는 단백질, 이를 인코딩한 핵산, 및 mrsa 감염을 예방 및 치료하기 위한 조성물 및 그의 용도
KR102277469B1 (ko) 2011-12-12 2021-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
EP2836505B1 (de) 2012-04-10 2019-01-23 The Trustees Of The University Of Pennsylvania Humanes respiratorisches synzytialvirus-consensus-antigene, nucleinsäurekonstrukte und impfstoffe daraus sowie verwendungsverfahren dafür
WO2014165291A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
AU2014228405B2 (en) 2013-03-15 2017-05-11 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
CN114045295A (zh) 2013-03-15 2022-02-15 宾夕法尼亚大学理事会 口蹄疫病毒(fmdv)共有蛋白、其编码序列以及由其制造的疫苗
US11338029B2 (en) 2017-12-13 2022-05-24 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting PRAME and uses thereof
US11235044B2 (en) 2017-12-13 2022-02-01 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting MUC16 and uses thereof
EP3723810A4 (de) 2017-12-13 2022-02-23 Inovio Pharmaceuticals, Inc. Gegen mesothelin gerichtete krebsvakzine und deren verwendungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines

Also Published As

Publication number Publication date
HU205262B (en) 1992-04-28
ATE137673T1 (de) 1996-05-15
AU640344B2 (en) 1993-08-26
CA1335661C (en) 1995-05-23
HU894750D0 (en) 1990-02-28
FI894446A (fi) 1989-09-22
HUT53810A (en) 1990-12-28
EP0368966A4 (en) 1991-01-09
EP0368966A1 (de) 1990-05-23
PT90075B (pt) 1994-05-31
DE68926431T2 (de) 1996-10-31
FI100945B (fi) 1998-03-31
AU3552089A (en) 1989-10-16
WO1989009063A1 (en) 1989-10-05
US5077044A (en) 1991-12-31
JPH02503868A (ja) 1990-11-15
PT90075A (pt) 1989-11-10
EP0368966B1 (de) 1996-05-08
FI894446A0 (fi) 1989-09-20

Similar Documents

Publication Publication Date Title
DE68926431D1 (de) Nichtrevertierende lebende shigella-impfstoffe
DK353686D0 (da) Levende ikke-virulent salmonella-vaccine og fremgangsmaade til fremstilling heraf
US4460575A (en) Vaccinal complex containing a specific antigen and vaccine containing it
HU911440D0 (en) Process for producing polypeptones
Kew et al. Evolution of the oral polio vaccine strains in humans occurs by both mutation and intramolecular recombination.
DE69231907T2 (de) Stabile pura-Vektoren und ihre Verwendung
EP0500699A4 (en) Cross-protective salmonella vaccines
DE88166T1 (de) Verfahren zum exprimieren eines gens.
CA2011654A1 (en) Recombinant poxvirus host range selection system
JP2009513155A (ja) 連鎖球菌のための流加培養法
BR9106982A (pt) Vacine e processo para fornecer protecao umunologica contra doenca de rotavirus em seres humanos,rotavirus isolado,cepa de rotavirus isolado,rotavirus reagrupado em intergenogrupo humano isolado,e processo de aumentar titulos de anticorpo neutralizante
CA2427475A1 (en) Purification of hbv antigens for use in vaccines
HU890702D0 (en) Vaccine and process for producing it
US20070031447A1 (en) Method of isolating biologically active fraction containing clinically acceptable native S-lipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides
BR9608894A (pt) Produtos extracelulares abundantes e processos para suas producões e usos
ZA918876B (en) Avirulent microbes and uses therefor:salmonella typhi
AU3038192A (en) Serpulina hyodysenteriae vaccine
US6764687B1 (en) Live attenuated bacteria for use in a vaccine
AU532982B2 (en) Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2- carboxylic acid esters
US20050238657A1 (en) Defective entities and uses therefor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee